Han Ting-Ting, Wang Li, Fan Lei, Xu Ji, Li Jian-Yong, Xu Wei
Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Provincial People's Hospital, Nanjing 210029, Jiangsu Province, China.
Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Provincial People's Hospital, Nanjing 210029, Jiangsu Province, China. E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Feb;22(1):104-7. doi: 10.7534/j.issn.1009-2137.2014.01.021.
Tonsil is the most frequent site of the head and neck non-Hodgkin's lymphoma (NHL), and the diffuse large B cell lymphoma (DLBCL) is the most common pathological type in tonsil NHL. The aim of this study was to investigate the characteristics of clinical manifestation, immunophenotype, prognostic factor of primary tonsil DLBCL and its treatment strategy. The clinical data of 7 newly diagnosed patients with primary tonsil DLBCL from October 2009 to February 2013 were analyzed retrospectively. The results indicated that the pharynx or sore throat as the fist symptom was found in all patients. Out of 7 cases, 3 was in Ann Arbor stage I (42.8%), a case was in stage II (57.1%). Pathological immunohistochemical detection showed that the CD10 positive rate was 100%, BCL-2 positive rate was 83.3%, BCL-6 positive rate was 71.4%, Ki-67 ≥ 70% was 66.7%. They were all sensitive to chemotherapy and radiotherapy. Following up 4 to 40 months, they were all alive. It is concluded that most patients with primary tonsil DLBCL are at early stage, have an obvious characteristics of onset ages, clinical manifestations, pathological histology and achieve better remission through combined chemotherapy and radiotherapy.
扁桃体是头颈部非霍奇金淋巴瘤（NHL）最常见的发病部位，而弥漫性大B细胞淋巴瘤（DLBCL）是扁桃体NHL最常见的病理类型。本研究旨在探讨原发性扁桃体DLBCL的临床表现、免疫表型、预后因素及其治疗策略。回顾性分析了2009年10月至2013年2月期间7例新诊断的原发性扁桃体DLBCL患者的临床资料。结果显示，所有患者均以咽部不适或咽痛为首发症状。7例患者中，3例为Ann Arbor I期（42.8%），4例为II期（57.1%）。病理免疫组化检测显示，CD10阳性率为100%，BCL-2阳性率为83.3%，BCL-6阳性率为71.4%，Ki-67≥70%为66.7%。所有患者对化疗和放疗均敏感。随访4至40个月，所有患者均存活。结论是，大多数原发性扁桃体DLBCL患者处于早期阶段，在发病年龄、临床表现、病理组织学方面具有明显特征，通过联合化疗和放疗可获得较好的缓解。
